NASDAQ · OMCL
Healthcare · Medical - Healthcare Information Services
$32.63
Up+$0.09 (+0.28%)
Updated Sep 16, 2026, 4:26 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OMCL closed at $32.63 after 20 trading sessions, down 9.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $33.13 | $33.35 | $32.23 | $32.63 | 642.62K |
| Sep 14, 2026 | $33.23 | $33.63 | $32.905 | $33.51 | 395.75K |
| Sep 11, 2026 | $32.88 | $33.015 | $32.32 | $32.79 | 483.65K |
| Sep 10, 2026 | $33.26 | $33.37 | $32.12 | $32.25 | 534.3K |
| Sep 9, 2026 | $33.49 | $33.675 | $32.8301 | $33.64 | 467.95K |
| Sep 8, 2026 | $33.75 | $35.30 | $33.54 | $33.88 | 571.11K |
| Sep 4, 2026 | $34.36 | $34.695 | $34.00 | $34.37 | 873.12K |
| Sep 3, 2026 | $35.09 | $35.375 | $34.41 | $34.82 | 673.32K |
| Sep 2, 2026 | $34.51 | $35.29 | $34.26 | $34.71 | 634.54K |
| Sep 1, 2026 | $34.70 | $35.605 | $34.07 | $34.51 | 805.57K |
| Aug 31, 2026 | $32.82 | $35.22 | $32.53 | $35.16 | 1.04M |
| Aug 28, 2026 | $33.52 | $33.76 | $32.865 | $33.08 | 538.72K |
| Aug 27, 2026 | $33.38 | $33.79 | $33.21 | $33.41 | 436.79K |
| Aug 26, 2026 | $33.22 | $33.88 | $32.96 | $33.45 | 627.18K |
| Aug 25, 2026 | $34.91 | $34.91 | $33.16 | $33.22 | 667.01K |
| Aug 24, 2026 | $35.56 | $35.66 | $34.44 | $34.66 | 512.01K |
| Aug 21, 2026 | $35.72 | $35.95 | $35.17 | $35.58 | 777.12K |
| Aug 20, 2026 | $36.21 | $36.5526 | $35.30 | $35.50 | 582.11K |
| Aug 19, 2026 | $36.10 | $37.30 | $36.10 | $36.43 | 667.43K |
| Aug 18, 2026 | $36.31 | $37.26 | $35.85 | $35.97 | 947.79K |
The latest Smart Investors Daily articles mentioning OMCL.
OMCL research
Company profile and research snapshot.
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | Keybanc | Overweight | — |
| Jul 31, 2026 | Wells Fargo | Overweight | — |
| Apr 29, 2026 | Keybanc | Overweight | — |
| Apr 23, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Yahoo · Sep 10, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Yahoo · Sep 3, 2026
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability,
Yahoo · Aug 31, 2026
FORT WORTH, Texas, August 31, 2026--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OMCL.
